• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

    3/4/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email

    - Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity

    - Topline data readout planned for early 2026

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R).

    PIPE-791 is being evaluated for the treatment of chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP). The Company expects to enroll approximately 40 patients at up to five sites in the U.S., and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain trial in early 2026.

    "With its unique mechanistic action, PIPE-791 has the potential to modify the maladaptive changes associated with chronic pain," said Stephen Huhn, Chief Medical Officer, Contineum Therapeutics. "This trial was designed to inform our decision-making on further advancing the chronic pain program. We're excited for the prospect that PIPE-791 may provide a potentially differentiated, non-opioid treatment option for patients with OA and LBP."

    Chronic pain is often associated with neuropathic symptoms caused by aberrant signaling in the central nervous system (CNS) leading to heightened sensitivity to painful stimuli. LPA1 activation has been shown preclinically to contribute to persistent hypersensitivity, characteristic of neuropathic pain, by promoting the demyelination of nerve fibers, increasing neuronal excitability and enhancing neuroinflammatory responses in the CNS. By selectively blocking LPA1 receptor activity, an LPA1 antagonist could modify the maladaptive changes in the CNS and subsequently reduce pain.

    About Contineum Therapeutics

    Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.

    Forward-Looking Statements

    Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company's clinical trial and product development plans and timelines, including, but not limited to, the expected timing of the topline data from the PIPE-791 Phase 1b chronic pain trial; the indications, anticipated benefits of, and market opportunities for its drug candidates; its cash runway; its business strategies and plans; and the quotations of the Company's management. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control and may cause its actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of earlier preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company's drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; risks associated with reliance on third parties to successfully conduct clinical trials and, in the case of PIPE-307, the Company's reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PIPE-307 for any other indication other than RRMS and, after completion of the Company's PIPE-307 Phase 2 VISTA trial, Janssen Pharmaceutica NV's decision, in its sole discretion, whether or not to further develop PIPE-307 for RRMS; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company's license agreement with Janssen Pharmaceutica NV may not result in the successful development of PIPE-307; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflict may adversely affect our business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company's business, operations and results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in its most recent filing on Form 10-Q and in other filings that it makes with the SEC from time to time. These documents are available on the Company's website at www.contineum-tx.com under the Investor section and on the SEC's website at www.sec.gov. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250304221906/en/

    Steve Kunszabo

    Contineum Therapeutics

    Senior Director, Investor Relations & Corporate Communications

    858-649-1158

    [email protected]

    Get the next $CTNM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    6/20/2025Outperform
    William Blair
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing. "In early June, consistent with our protocol, we enr

      6/25/25 8:15:00 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

      ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magni

      6/23/25 8:45:00 PM ET
      $ARTV
      $CTNM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI

      5/15/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    SEC Filings

    See more
    • Contineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

      6/26/25 4:07:21 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Contineum Therapeutics Inc.

      EFFECT - Contineum Therapeutics, Inc. (0001855175) (Filer)

      5/27/25 12:15:13 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.

      SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)

      5/15/25 4:30:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Boyce Sarah

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:50:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schimmelpennink Evert B.

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:47:53 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brady Todd R.

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:46:34 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Contineum Therapeutics

      William Blair initiated coverage of Contineum Therapeutics with a rating of Outperform

      6/20/25 7:53:37 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

      Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

      10/22/24 6:13:41 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Contineum Therapeutics Inc.

      SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

      11/14/24 4:38:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care